Efficacy of liraglutide on glycemic endpoints in people of Western European and South Asian descent with T2DM using multiple daily insulin injections: results of the MAGNA VICTORIA studies
| Autor: | Ingrid M. Jazet, Huub J. van Eyk, Petronella H Geelhoed-Duijvestijn, Aan V. Kharagjitsingh, Maurice B. Bizino, Elisabeth H.M. Paiman, H.J. Lamb, Patrick C.N. Rensen, Johannes W. A. Smit |
|---|---|
| Přispěvatelé: | Pathology/molecular and cellular medicine, Diabetes Clinic, Diabetes Pathology & Therapy |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Context (language use) Subgroup analysis 030204 cardiovascular system & hematology Placebo 03 medical and health sciences 0302 clinical medicine Endocrinology Diabetes mellitus Internal medicine Type 2 diabetes mellitus Internal Medicine Clinical endpoint Medicine South Asian Glycemic liraglutide business.industry Liraglutide General Medicine medicine.disease Multiple daily insulin injections Metformin Glucagon-like peptide-1 receptor agonist business medicine.drug |
| DOI: | 10.1007/s00592-020-01635-0 |
| Popis: | Aims: Data on the effect of liraglutide on glycemic endpoints in people with T2DM using multiple daily insulin injections (MDI) are scarce, especially in the context of ethnicity. Methods: This is a secondary analysis of the placebo-controlled randomized clinical “MAGNA VICTORIA” trials in Western European (WE) and South Asian (SA) people with T2DM. Participants had inadequate glycemic control despite using metformin and/or sulfonylurea derivatives and/or insulin. Participants were assigned to liraglutide (1.8 mg) or placebo for 6 months, in addition to standard care. The primary endpoint number of participants reaching target HbA1c was compared for liraglutide versus placebo in the complete dataset and MDI-treated participants using Chi-square test. Liraglutide’s efficacy in WE and SA was compared using a generalized linear model. Results: Forty-five subjects were randomized to liraglutide and 51 to placebo. In each group, one participant did not complete the study. Liraglutide-treated patients reached target HbA1c more frequently: 23/45 (51%) vs 11/51 (22%), relative probability 2.4 (1.3–4.3), p = 0.002. Subgroup analysis in 43 MDI participants showed that the proportion reaching target HbA1c using liraglutide was significantly higher than in placebo: 9/22 (41%) vs 1/21 (5%), p = 0.005. There was no difference between WE and SA in terms of liraglutide efficacy (p = 0.18). Conclusions: Liraglutide treatment resulted in increased chance of reaching target HbA1c as compared to placebo. Liraglutide efficacy was sustained in participants using MDI regimens and those of SA descent. Liraglutide should be considered for T2DM people with inadequate glycemic control despite MDI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|